
MUSTANG BIO, INC. — Investor Relations & Filings
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-05-05 | English | |
| 8-K - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-04-17 | English | |
| Major Shareholding Notification 2026 | 2026-01-05 | English | |
| Director's Dealing 2026 | 2026-01-05 | English | |
| OWNERSHIP DOCUMENT | 2025-12-30 | English | |
| OWNERSHIP DOCUMENT | 2025-12-30 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 41519352 | 10-Q - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-05-05 | English | ||
| 34661932 | 8-K - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-04-17 | English | ||
| 12973079 | Major Shareholding Notification 2026 | 2026-01-05 | English | ||
| 12973078 | Director's Dealing 2026 | 2026-01-05 | English | ||
|
2025
11 filings
| |||||
| 12973080 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973081 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973082 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973084 | 8-K | 2025-12-23 | English | ||
| 12973083 | DEF 14A | 2025-12-03 | English | ||
| 12973085 | 10-Q | 2025-11-07 | English | ||
| 12973086 | Major Shareholding Notification 2025 | 2025-10-01 | English | ||
| 12973089 | Director's Dealing 2025 | 2025-10-01 | English | ||
| 12973087 | 424B5 | 2025-09-05 | English | ||
| 12973088 | Major Shareholding Notification 2025 | 2025-08-12 | English | ||
| 12973090 | 10-Q | 2025-08-08 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ANTEROGEN CO., LTD.
Develops and commercializes cell therapies and orphan drugs…
|
065660 | KR | Manufacturing |
|
Antibiotice S.A.
Pharmaceutical firm manufacturing generic medicines, anti-i…
|
ATB | RO | Manufacturing |
|
Anuh Pharma Ltd.
Manufacturer of APIs and bulk drugs specializing in Macroli…
|
ANUHPHR | IN | Manufacturing |
|
Apellis Pharmaceuticals, Inc.
Biopharmaceutical company developing therapies by targeting…
|
APLS | US | Manufacturing |
|
Apeloa Pharmaceutical Co.,Ltd.
Integrated provider of APIs, CDMO services, and finished dr…
|
000739 | CN | Manufacturing |
|
APEX HEALTHCARE BERHAD
Integrated pharmaceutical group manufacturing and distribut…
|
— | MY | Manufacturing |
|
ApicHope Pharmaceutical Group Co.,Ltd
Pharmaceutical firm focused on pediatric, chronic, and card…
|
300723 | CN | Manufacturing |
|
Apimeds Pharmaceuticals US, Inc.
Clinical-stage biopharma developing a bee venom drug and AI…
|
APUS | US | Manufacturing |
|
Apogee Therapeutics, Inc.
Clinical-stage biotech developing biologics for immunologic…
|
APGE | US | Manufacturing |
|
Apollomics Inc.
Clinical-stage biotech developing innovative oncology and c…
|
APLM | US | Manufacturing |
MUSTANG BIO, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35167/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35167 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35167 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35167 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35167}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MUSTANG BIO, INC. (id: 35167)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.